Metabolic perturbation sensitizes human breast cancer to NK cell-mediated cytotoxicity by increasing the expression of MHC class I chain-related A/B.

abstract：:Three recent publications identified the TNF/TNR2 pathway as a new target to reduce graft-versus-host-disease through regulatory T cells activation or to potentially switch on a strong anti-leukemic effect through regulatory T cells blockade in allogeneic hematopoietic stem cell transplantation. This identified the TN...

journal_title：Oncoimmunology

authors： Cohen JL,Wood KJ

更新日期：2017-09-21 00:00:00

abstract：:CD96 is a transmembrane glycoprotein Ig superfamily receptor, expressed on various T cell subsets and NK cells, that interacts with nectin and nectin-like proteins, including CD155/polio virus receptor (PVR). Here, we have compared three rat anti-mouse CD96 mAbs, including two that block CD96-CD155 (3.3 and 6A6) and o...

journal_title：Oncoimmunology

authors： Roman Aguilera A,Lutzky VP,Mittal D,Li XY,Stannard K,Takeda K,Bernhardt G,Teng MWL,Dougall WC,Smyth MJ

更新日期：2018-02-01 00:00:00

abstract：:Cutaneous angiosarcoma (CAS) is a malignant sarcoma with poor prognosis. Programmed cell death-1 (PD-1)/programmed cell death-1 ligand-1 (PD-L1) expression reflects antitumor immunity, and is associated with patient prognosis in various cancers. The purpose of this study is to investigate the relationship between PD-1...

journal_title：Oncoimmunology

authors： Honda Y,Otsuka A,Ono S,Yamamoto Y,Seidel JA,Morita S,Hirata M,Kataoka TR,Takenouchi T,Fujii K,Kanekura T,Okubo Y,Takahashi K,Yanagi T,Hoshina D,Hata H,Abe R,Fujimura T,Funakoshi T,Yoshino K,Masuzawa M,Amoh Y,T

更新日期：2016-11-04 00:00:00

abstract：:Galectin-9 has emerged as a promising biological target for cancer immunotherapy due to its role as a regulator of macrophage and T-cell differentiation. In addition, its expression in tumor cells modulates tumor cell adhesion, metastasis, and apoptosis. Malignant mesothelioma (MM) is an aggressive neoplasm of the mes...

journal_title：Oncoimmunology

authors： Bertino P,Premeaux TA,Fujita T,Haun BK,Marciel MP,Hoffmann FW,Garcia A,Yiang H,Pastorino S,Carbone M,Niki T,Berestecky J,Hoffmann PR,Ndhlovu LC

更新日期：2019-04-17 00:00:00

abstract：:Immune adjuvants aimed at initiating or re-activating host immunity against poorly immunogenic cancers represent a potential tool for immunotherapy. By employing the natural killer T (NKT) cell agonist α-galactosylceramide in a whole tumor cell therapeutic vaccine approach, we have achieved potent suppression of estab...

journal_title：Oncoimmunology

authors： Mattarollo SR,Smyth MJ

更新日期：2013-01-01 00:00:00

abstract：:The blockade of the PD-1 pathway can increase the production of interferon γ by tumor-specific T cells located within or in the proximity of the malignant lesion, thereby increasing the chemokine-dependent trafficking of immune effector cells. This can boost the efficacy of adoptive T-cell therapy to achieve superior ...

journal_title：Oncoimmunology

authors： Peng W,Lizée G,Hwu P

更新日期：2013-02-01 00:00:00

abstract：:Tumor-associated macrophages (TAM) are immunosuppressive cells that can massively accumulate in the tumor microenvironment. In patients with ovarian cancer, their density is correlated with poor prognosis. Targeting mediators that control the generation or the differentiation of immunoregulatory macrophages represents...

journal_title：Oncoimmunology

authors： d'Almeida SM,Kauffenstein G,Roy C,Basset L,Papargyris L,Henrion D,Catros V,Ifrah N,Descamps P,Croue A,Jeannin P,Grégoire M,Delneste Y,Tabiasco J

更新日期：2016-04-28 00:00:00

abstract：:Tumor-infiltrating lymphocytes (TILs) are correlated to prognosis of several kinds of cancer. Most studies focused on T cells, while the role of tumor-associated B cells (TABs) has only recently gained more attention. TABs contain subpopulations with distinct functions, potentially promoting or inhibiting immune respo...

journal_title：Oncoimmunology

authors： Schlößer HA,Thelen M,Lechner A,Wennhold K,Garcia-Marquez MA,Rothschild SI,Staib E,Zander T,Beutner D,Gathof B,Gilles R,Cukuroglu E,Göke J,Shimabukuro-Vornhagen A,Drebber U,Quaas A,Bruns CJ,Hölscher AH,Von Bergwelt-Bai

更新日期：2018-11-02 00:00:00

abstract：:Introduction: Advanced non-small cell lung cancer (NSCLC) is traditionally treated with platinum-based chemotherapy and radiotherapy. Since immunotherapy holds promise for treating advanced NSCLC, we assessed the systemic effects of the traditional therapies for NSCLC on immune cell composition and function. Methods: ...

journal_title：Oncoimmunology

authors： Talebian Yazdi M,Schinkelshoek MS,Loof NM,Taube C,Hiemstra PS,Welters MJ,van der Burg SH

更新日期：2016-11-08 00:00:00

abstract：:Oncolytic virotherapy is an emergent promising therapeutic approach for the treatment of cancer. We have constructed a vaccinia virus (WR strain) deleted for thymidine kinase (TK) and ribonucleotide reductase (RR) genes that expressed the fusion suicide gene FCU1 derived from the yeast cytosine deaminase and uracil ph...

journal_title：Oncoimmunology

authors： Fend L,Remy-Ziller C,Foloppe J,Kempf J,Cochin S,Barraud L,Accart N,Erbs P,Fournel S,Préville X

更新日期：2015-10-06 00:00:00

abstract：:Type I interferon (IFN) release by irradiated cancer cells is paramount for radiation therapy to elicit anticancer immunity. Our findings demonstrate that mitochondrial outer membrane permeabilization (MOMP) triggered by RT enables exposure of mitochondrial DNA to the cytosol, hence setting off CGAS-driven type I IFN ...

journal_title：Oncoimmunology

authors： Yamazaki T,Galluzzi L

更新日期：2020-07-22 00:00:00

abstract：:Glioblastoma is an aggressive primary brain cancer. Given our interest in novel immunotherapies, we have recently shown that inhibiting CTLA-4, PD-L1 and IDO results in a dramatic survival advantage in mice with brain tumors. Our preclinical study supports the rapid translation of this approach into phase I clinical t...

journal_title：Oncoimmunology

authors： Wainwright DA,Lesniak MS

更新日期：2014-05-15 00:00:00

abstract：:Sepsis-induced immune dysfunctions are likely to impact on malignant tumor growth. Sequential sepsis-then-cancer models of tumor transplantation in mice recovering from sepsis have shown that the post-septic immunosuppressive environment was able to promote tumor growth. We herein addressed the impact of sepsis on pre...

journal_title：Oncoimmunology

authors： Vigneron C,Mirouse A,Merdji H,Rousseau C,Cousin C,Alby-Laurent F,Mira JP,Chiche JD,Llitjos JF,Pène F

更新日期：2019-07-19 00:00:00

abstract：:Background. Glioblastoma (GBM) is the most common malignant brain tumor in adults and is nearly always fatal. Emerging evidence suggests that human Cytomegalovirus (HCMV) is present in 90-100% of GBMs and that add-on antiviral treatment for HCMV show promise to improve survival. Methods. In a randomized, placebo-contr...

journal_title：Oncoimmunology

authors： Rahbar A,Peredo I,Solberg NW,Taher C,Dzabic M,Xu X,Skarman P,Fornara O,Tammik C,Yaiw K,Wilhelmi V,Assinger A,Stragliotto G,Söderberg-Naucler C

更新日期：2015-02-25 00:00:00

abstract：:In our previous studies, we have shown that patients with serous ovarian carcinoma in advanced surgical stage disease have a particularly poor prognosis if they carry the HLA-A*02 genotype. This represent a stronger prognostic factor than loss or downregulation of the MHC class I heavy chain (HC) on tumor cells. In th...

journal_title：Oncoimmunology

authors： Andersson E,Poschke I,Villabona L,Carlson JW,Lundqvist A,Kiessling R,Seliger B,Masucci GV

更新日期：2015-07-25 00:00:00

abstract：:Low expression of RhoGDI2 is associated with poor outcome in cancer patients. In animal models, RhoGDI2 suppresses lung metastasis by reducing the expression of the proteoglycan versican, whose levels portend poor patient prognosis. Versican promotes metastasis through enhanced tumor migration and creation of an infla...

journal_title：Oncoimmunology

authors： Said N,Theodorescu D

更新日期：2012-10-01 00:00:00

abstract：:Kynurenine formation by tryptophan-catabolic indoleamine-2,3-dioxygenase 1 (IDO1) plays a key role in tumor immune evasion and inhibition of IDO1 is efficacious in preclinical models of breast cancer. As the response of breast cancer to immune checkpoint inhibitors may be limited, a better understanding of the express...

journal_title：Oncoimmunology

authors： Dewi DL,Mohapatra SR,Blanco Cabañes S,Adam I,Somarribas Patterson LF,Berdel B,Kahloon M,Thürmann L,Loth S,Heilmann K,Weichenhan D,Mücke O,Heiland I,Wimberger P,Kuhlmann JD,Kellner KH,Schott S,Plass C,Platten M,Gerhä

更新日期：2017-01-03 00:00:00

abstract：:PD-1 engagement on the surface of effector T cells strongly suppresses their cytotoxic function, which constitutes a major obstacle for T cell-mediated anti-tumor activities. Surprisingly, PD-1 is strongly upregulated in T cells, engaging its ligand PD-L1 during antigen presentation. However, our recent published data...

journal_title：Oncoimmunology

authors： Karwacz K,Arce F,Bricogne C,Kochan G,Escors D

更新日期：2012-01-01 00:00:00

abstract：:We assessed the tolerability and antitumor activity of solitomab, a bispecific T-cell engager (BiTE®) antibody construct targeting epithelial cell adhesion molecule (EpCAM). Patients with relapsed/refractory solid tumors not amenable to standard therapy received solitomab as continuous IV infusion in a phase 1 dose-es...

journal_title：Oncoimmunology

authors： Kebenko M,Goebeler ME,Wolf M,Hasenburg A,Seggewiss-Bernhardt R,Ritter B,Rautenberg B,Atanackovic D,Kratzer A,Rottman JB,Friedrich M,Vieser E,Elm S,Patzak I,Wessiepe D,Stienen S,Fiedler W

更新日期：2018-04-18 00:00:00

abstract：:Removal of immuno-suppression has been reported to enhance antitumor immunity primed by checkpoint inhibitors. Although PD-1 blockade failed to control tumor growth in a transgenic murine neuroblastoma model, concurrent inhibition of colony stimulating factor 1 receptor (CSF-1R) by BLZ945 reprogrammed suppressive myel...

journal_title：Oncoimmunology

authors： Eissler N,Mao Y,Brodin D,Reuterswärd P,Andersson Svahn H,Johnsen JI,Kiessling R,Kogner P

更新日期：2016-09-09 00:00:00

abstract：:A missense mutation in RHOA encoding p.Gly17 Val has been reported to occur frequently in angioimmunoblastic T-cell lymphoma (AITL). Here, we describe a murine model which expresses the human RHOA mutant gene product in a T-cell specific manner and develops AITL-like symptoms. Most transgenic mice feature with latency...

journal_title：Oncoimmunology

authors： Lee GJ,Jun Y,Yoo HY,Jeon YK,Lee D,Lee S,Kim J

更新日期：2020-05-13 00:00:00

abstract：:Blockade of the PD-1 receptor has revolutionized the treatment of metastatic melanoma, with significant increases in overall survival (OS) and a dramatic improvement in patient quality of life. Despite the success of this approach, the number of benefitting patients is limited and there is a need for predictive biomar...

journal_title：Oncoimmunology

authors： Pico de Coaña Y,Wolodarski M,van der Haar Àvila I,Nakajima T,Rentouli S,Lundqvist A,Masucci G,Hansson J,Kiessling R

更新日期：2020-08-28 00:00:00

abstract：:We recently completed a phase 1 clinical trial demonstrating the safety of a mammaglobin-A DNA vaccine in patients with metastatic breast cancer. We are currently enrolling patients with early stage breast cancer in a phase 1b clinical trial. The mammaglobin-A DNA vaccine will be administered concurrently with neoadju...

journal_title：Oncoimmunology

authors： Kim SW,Goedegebuure P,Gillanders WE

更新日期：2016-02-26 00:00:00

abstract：:A cancer-promoting role of fibrogenesis in the liver has long been speculated; however, the molecular mechanisms regarding this phenomenon are largely unknown. We demonstrated in our previous study that macrophage-derived S100A4 promotes liver fibrosis via activation of hepatic stellate cells; however, whether and how...

journal_title：Oncoimmunology

authors： Li Y,Wang J,Song K,Liu S,Zhang H,Wang F,Ni C,Zhai W,Liang J,Qin Z,Zhang J

更新日期：2020-02-14 00:00:00

abstract：:Pancreatic cancer is characterized by expanded stroma with marked fibrosis. In Ijichi et al., we show that inhibiting CXCR2 disrupts tumor-stromal interactions and improves survival of a genetically-engineered mouse model recapitulating human pancreatic cancer. Targeting CXCLs/CXCR2 axis in the tumor microenvironment ...

journal_title：Oncoimmunology

authors： Ijichi H

更新日期：2012-07-01 00:00:00

abstract：:PD-L1 expression and regulation by mesenchymal tumor cells remain largely undefined. Here, we report that among different EMT-activated MCF7 human breast cancer cell clones, PD-L1 was differentially upregulated in MCF7 sh-WISP2, MCF7-1001/2101, and MDA-MB-231 cells but not in MCF7 SNAI1 and MCF7 SNAI1-6SA cells. Mecha...

journal_title：Oncoimmunology

authors： Noman MZ,Janji B,Abdou A,Hasmim M,Terry S,Tan TZ,Mami-Chouaib F,Thiery JP,Chouaib S

更新日期：2017-01-23 00:00:00

abstract：:The potential of a tumor cell to metastasize profoundly depends on its microenvironment, or "niche" interactions with local components. Tumor-associated-macrophages (TAMs) are the most abundant subpopulation of tumor stroma and represent a key component of tumor microenvironment. The dynamic interaction of cancer cell...

journal_title：Oncoimmunology

authors： Baghel KS,Tewari BN,Shrivastava R,Malik SA,Lone MU,Jain NK,Tripathi C,Kanchan RK,Dixit S,Singh K,Mitra K,Negi MP,Srivastava M,Misra S,Bhatt ML,Bhadauria S

更新日期：2016-07-15 00:00:00

abstract：:Oncolytic viruses (OVs) preferentially target and kill cancer cells without affecting healthy cells through a multi-modal mechanism of action. While historically the direct killing activity of OVs was considered the primary mode of action, initiation or augmentation of a host antitumor immune response is now considere...

journal_title：Oncoimmunology

authors： Davola ME,Mossman KL

更新日期：2019-03-28 00:00:00

abstract：:The redirection of T cell activity using bispecific antibodies is one of the most promising cancer immunotherapy approaches currently in development, but it is limited by cytokine storm-related toxicities, as well as the pharmacokinetics and tumor-penetrating capabilities of current bispecific antibody formats. Here, ...

journal_title：Oncoimmunology

authors： Harwood SL,Alvarez-Cienfuegos A,Nuñez-Prado N,Compte M,Hernández-Pérez S,Merino N,Bonet J,Navarro R,Van Bergen En Henegouwen PMP,Lykkemark S,Mikkelsen K,Mølgaard K,Jabs F,Sanz L,Blanco FJ,Roda-Navarro P,Alvarez-Vallina L

更新日期：2017-09-27 00:00:00

abstract：:When naive mice receive short Zfra peptides via tail vein injections, they develop lifetime resistance to growth of many cancer xenografts, due to activation of a novel spleen memory Hyal-2+ CD3- CD19- Z lymphocyte. In vitro education of spleen cells with Zfra activates Z cell for conferring memory anticancer response...

journal_title：Oncoimmunology

authors： Su WP,Wang WJ,Sze CI,Chang NS

更新日期：2016-07-28 00:00:00